Autolus Therapeutics (AUTL) Competitors $1.33 -0.18 (-11.92%) Closing price 04:00 PM EasternExtended Trading$1.38 +0.05 (+3.76%) As of 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AUTL vs. KNSA, JANX, TVTX, MESO, VERA, IMCR, ANIP, SDGR, IDYA, and AMPHShould you be buying Autolus Therapeutics stock or one of its competitors? The main competitors of Autolus Therapeutics include Kiniksa Pharmaceuticals (KNSA), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), Mesoblast (MESO), Vera Therapeutics (VERA), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry. Autolus Therapeutics vs. Kiniksa Pharmaceuticals Janux Therapeutics Travere Therapeutics Mesoblast Vera Therapeutics Immunocore ANI Pharmaceuticals Schrödinger IDEAYA Biosciences Amphastar Pharmaceuticals Autolus Therapeutics (NASDAQ:AUTL) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, community ranking, institutional ownership, media sentiment and risk. Does the media refer more to AUTL or KNSA? In the previous week, Autolus Therapeutics had 4 more articles in the media than Kiniksa Pharmaceuticals. MarketBeat recorded 6 mentions for Autolus Therapeutics and 2 mentions for Kiniksa Pharmaceuticals. Kiniksa Pharmaceuticals' average media sentiment score of 1.78 beat Autolus Therapeutics' score of -0.11 indicating that Kiniksa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Autolus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate AUTL or KNSA? Autolus Therapeutics presently has a consensus target price of $9.32, suggesting a potential upside of 517.22%. Kiniksa Pharmaceuticals has a consensus target price of $37.17, suggesting a potential upside of 70.80%. Given Autolus Therapeutics' higher probable upside, analysts clearly believe Autolus Therapeutics is more favorable than Kiniksa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Autolus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Kiniksa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is AUTL or KNSA more profitable? Autolus Therapeutics has a net margin of 0.00% compared to Kiniksa Pharmaceuticals' net margin of -2.36%. Kiniksa Pharmaceuticals' return on equity of -7.31% beat Autolus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Autolus TherapeuticsN/A -63.65% -36.54% Kiniksa Pharmaceuticals -2.36%-7.31%-5.95% Which has more volatility & risk, AUTL or KNSA? Autolus Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Do insiders and institutionals have more ownership in AUTL or KNSA? 72.8% of Autolus Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals shares are owned by institutional investors. 25.7% of Autolus Therapeutics shares are owned by company insiders. Comparatively, 54.6% of Kiniksa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, AUTL or KNSA? Kiniksa Pharmaceuticals has higher revenue and earnings than Autolus Therapeutics. Kiniksa Pharmaceuticals is trading at a lower price-to-earnings ratio than Autolus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAutolus Therapeutics$10.12M39.70-$208.38M-$0.86-1.76Kiniksa Pharmaceuticals$423.24M3.73$14.08M-$0.61-35.67 Does the MarketBeat Community prefer AUTL or KNSA? Autolus Therapeutics received 56 more outperform votes than Kiniksa Pharmaceuticals when rated by MarketBeat users. Likewise, 68.15% of users gave Autolus Therapeutics an outperform vote while only 65.28% of users gave Kiniksa Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAutolus TherapeuticsOutperform Votes22968.15% Underperform Votes10731.85% Kiniksa PharmaceuticalsOutperform Votes17365.28% Underperform Votes9234.72% SummaryAutolus Therapeutics beats Kiniksa Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Remove Ads Get Autolus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AUTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUTL vs. The Competition Export to ExcelMetricAutolus TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$401.80M$2.98B$5.53B$7.50BDividend YieldN/A1.53%4.86%4.05%P/E Ratio-1.2530.4323.2318.08Price / Sales39.70383.25362.7586.83Price / CashN/A168.6838.1634.64Price / Book2.363.646.493.99Net Income-$208.38M-$72.06M$3.21B$247.18M7 Day Performance-9.04%-9.02%-4.90%-4.25%1 Month Performance-17.49%-16.50%-0.07%-6.87%1 Year Performance-72.60%-31.37%6.45%-3.73% Autolus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUTLAutolus Therapeutics2.2013 of 5 stars$1.33-11.9%$9.32+600.8%-72.5%$353.91M$10.12M-1.10330Analyst ForecastGap DownKNSAKiniksa Pharmaceuticals2.5213 of 5 stars$22.21-3.8%$37.17+67.3%+19.3%$1.61B$423.24M-158.63220Positive NewsGap DownJANXJanux Therapeutics2.0435 of 5 stars$27.00-7.2%$92.44+242.4%-25.7%$1.60B$10.59M-23.0830Gap DownTVTXTravere Therapeutics2.4772 of 5 stars$17.92-8.9%$30.62+70.8%+137.2%$1.59B$233.18M-4.37460Analyst ForecastNews CoverageGap DownMESOMesoblast1.7477 of 5 stars$12.48+3.1%$18.00+44.2%+83.5%$1.59B$5.67M0.0080Analyst RevisionNews CoverageGap DownVERAVera Therapeutics2.8875 of 5 stars$24.02-9.8%$64.67+169.2%-42.6%$1.53BN/A-9.2040News CoverageGap DownHigh Trading VolumeIMCRImmunocore1.7848 of 5 stars$29.67+0.3%$65.64+121.2%-54.4%$1.48B$310.20M-31.23320Positive NewsGap DownANIPANI Pharmaceuticals3.4545 of 5 stars$66.95-1.0%$79.75+19.1%+1.6%$1.46B$614.38M-121.73600Gap DownSDGRSchrödinger1.8428 of 5 stars$19.74-1.1%$32.29+63.6%-24.2%$1.44B$207.54M-8.44790Gap DownIDYAIDEAYA Biosciences3.1971 of 5 stars$16.38-3.9%$53.58+227.1%-63.1%$1.43B$7M-4.9680News CoveragePositive NewsHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.0936 of 5 stars$28.99+2.0%$43.50+50.1%-35.1%$1.38B$731.97M9.661,620Gap Down Remove Ads Related Companies and Tools Related Companies Kiniksa Pharmaceuticals Competitors Janux Therapeutics Competitors Travere Therapeutics Competitors Mesoblast Competitors Vera Therapeutics Competitors Immunocore Competitors ANI Pharmaceuticals Competitors Schrödinger Competitors IDEAYA Biosciences Competitors Amphastar Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AUTL) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Autolus Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Autolus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AUTL Stock Free AUTL Stock Alerts